ClinicalTrials.gg
CompletedNCT01444235Updated May 17, 2013

Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery

A Phase 2 interventional study of Custodiol-N and Custodiol in Coronary Artery Disease (CAD), sponsored by Dr. F. Köhler Chemie GmbH. Completed at 4 sites in Germany. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-05-17.

Sponsored by Dr. F. Köhler Chemie GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Enrollment
175th of 248
102 · median 265
Started
2011
with 18 others
Phase 2
19 of 365
1 open now
Registered
137th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 175th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2011, is one of 19 in phase 2, and was the 137th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

Comparison of the cardioprotective effects and safety of two cardioplegic solutions (solutions used during a cardiac arrest in the heart surgery) in patients undergoing cardiopulmonary bypass for coronary artery bypass surgery.

Read the detailed description

The objective of this investigation is to compare the cardioprotective effects and safety of two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients undergoing cardiopulmonary bypass for coronary artery bypass surgery. The study design is a prospective, double blind, multicenter, randomized, Phase III comparison study intended to demonstrate non-inferiority in surgical outcome between Custodiol and Custodiol-N as determined by CK-MB area under the curve (primary endpoint), catecholamine requirement(cumulative dose) and cardiac Troponin T, occurrence of comorbid events postoperatively (e.g., myocardial infarction).

03

Conditions studied

  • Coronary Artery Disease (CAD)

Keywords

  • CAD, ACVB
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The study population will be selected from patients of either sex with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery.

  1. Patients >/=35 and \</=80 years of age
  2. Male or female with 2 or 3 vessel coronary disease, who are scheduled for elective CBP surgery for coronary revascularisation
  3. Presence of definite CAD for which surgical intervention is deemed necessary, without evidence of ongoing infarction.

    Patients with unstable angina can be included as long as there is no objective (negative cardiac isoenzymes in the immediate six hours preceding CABG, current intravenous use of nitrate therapy) or subjective (absence of prolonged symptoms suggestive of coronary insufficiency that do not respond to pharmacologic intervention) evidence of myocardial necrosis.

  4. Eligibility for Swan-Ganz-Catheter
  5. Able to understand character and individual consequences of the clinical trial and to provide written to participate in the study
  6. No evidence of severe organic or psychiatric disease by history or physical examination
  7. No history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or no any history of drug abuse or addiction within 12 months of study enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Patients undergoing valve repair or replacement
  2. History of recent (\< 6 weeks) Q-wave myocardial infarction
  3. \< 35% (as assessed by any one of the following: contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)
  4. Patients on intra-aortic balloon devices or with history of previous coronary artery bypass surgery
  5. Pregnant or lactating patients
  6. Patients who have participated in any other studies within 30 days previous to enrollment
  7. Patients in cardiogenic shock (defined as a systolic BP \< 90 mmHg for over one hour despite inotropic and chronotropic support)
  8. Patients with severe chronic obstructive lung disease ( \< 50%)
  9. Previous cardiac valvular disease (clinical relevant)
  10. Dialysis or creatinine > 2 mmol/L
  11. BMS-Stent \< 4 weeks
  12. DES-Stent \< 6 month
  13. Guidance depended Plavix therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Active comparator
    Custodiol

    After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.

    Drug: Custodiol

  • Experimental
    Custodiol-N

    After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.

    Drug: Custodiol-N

Interventions

06

What researchers measure

Primary outcomes

  1. CK-MB area under the curve within 24 hours

    Measurements will be carried out at the following timepoints: 4,8,12,16,20,24 hours (± 30 min) after release of the aortic cross clamp

    Time frame: Up to 24 hours after the aortic clamp release

Secondary outcomes

  1. Catecholamine requirement

    Catecholamine requirement on surgical ICU within 24 hours

    Time frame: 24 hours (cumulative dose)

  2. CK-MB peak

    CK-MB peak on the days 2, 3, 4 and 5 after removal of aortic cross clamp

    Time frame: Up to day 5

  3. Mortality any time during post-op through Day 30

    Mortality will be documented at any time during post-op through Day 30

    Time frame: Up to Day 30

07

Study locations

4 sites
  • Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen
    Essen, 45147, Germany
  • Abt. Herzchirugie, Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena
    Jena, 07740, Germany
  • Herzzentrum Leipzig GmbH
    Leipzig, 04289, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2011
First posted
Sep 30, 2011
Start
Mar 2011
Primary completionActual
May 2012
CompletionActual
Jul 2012
Last update
May 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01444235
Lead sponsor
Dr. F. Köhler Chemie GmbH
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Mar 2011
Primary completion
May 2012
Completion
Jul 2012
Last update
May 17, 2013

Study contacts

Gabor Szabo, Prof. Dr.
principal investigator · Department of Cardiac Surgery of University of Heidelberg
Nikolaus Pizanis, Dr.
principal investigator · Klinik für Thorax- und Kardiovaskuläre Chirurgie, Universitätsklinikum Essen
Florian Wagner, Dr.
principal investigator · Klinik für Herz- und Gefäßchirurgie, Universitäts-Krankenhaus Eppendorf
Thorsten Doenst, Prof. Dr.
principal investigator · Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Jena
Martin Misfeld, Dr.
principal investigator · Herzzentrum Leipzig GmbH, Klinik für Herzchirurgie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Custodiol-N solution · Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride

Start the discussion